This month's healthcare newsletter brings you the latest in updates from Korea's fast-paced biopharma landscape, including notable changes to the public health insurance system - shifting Korea's co-pay model to one with fixed rates - and a second-stage pharmacogenetics initiative to bolster availability of local population test data.

Please refer to the attached document for detailed insights.